GlobeImmune (GBIM) Files $69M IPO
Tweet Send to a Friend
GlobeImmune, Inc. (Nasdaq: GBIM) filed a registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. The proposed maximum offering price is $69 million. GlobeImmune applied to list on the Nasdaq Global Market under the ticker, "GBIM."
The offering is being made through Wells Fargo Securities, Piper Jaffray, and JMP Securities.
GlobeImmune is a biopharmaceutical company focused on developing therapeutic products for cancer and infectious diseases based on our proprietary Tarmogen platform.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The offering is being made through Wells Fargo Securities, Piper Jaffray, and JMP Securities.
GlobeImmune is a biopharmaceutical company focused on developing therapeutic products for cancer and infectious diseases based on our proprietary Tarmogen platform.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Global Brass and Copper (BRSS) IPO Opens Higher
- Friday's Hot IPOs Get Even Hotter (MKTO) (DATA)
- Tableau Software (DATA) IPO now indicated $45-$48
Create E-mail Alert Related Categories
IPOsRelated Entities
Piper Jaffray, JMP Securities, Wells Fargo
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
